Immunome Inc (NASDAQ:IMNM) is surging Tuesday morning after the company reported the pre-clinical testing results of its antibody cocktail.
Immunome announced that its three-antibody cocktail, IMM-BCP-01, demonstrated neutralizing activity against the SARS-CoV-2 Delta variant. The company also said that IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms.
“IMM-BCP-01’s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19,” said Purnanand Sarma, president and CEO of Immunome.
Amid the recent resurgence of COVID-19 variants, the company said it plans to explore opportunities to expedite the development of its potential therapeutic.
Price Action: Immunome has traded as high as $63.78 and as low as $9.27 over a 52-week period.
At last check Tuesday, the stock was up 39.40% at $23.20.
